Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Strs Ohio

Strs Ohio increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 430.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,316 shares of the company’s stock after buying an additional 9,996 shares during the quarter. Strs Ohio’s holdings in Neurocrine Biosciences were worth $1,623,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NBIX. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 18.0% in the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock worth $462,652,000 after acquiring an additional 498,058 shares during the period. Geode Capital Management LLC lifted its stake in shares of Neurocrine Biosciences by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after purchasing an additional 34,457 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after purchasing an additional 88,522 shares during the period. Northern Trust Corp grew its holdings in shares of Neurocrine Biosciences by 31.9% during the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock worth $173,201,000 after purchasing an additional 295,470 shares during the period. Finally, Deerfield Management Company L.P. increased its position in shares of Neurocrine Biosciences by 1.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock worth $166,258,000 after purchasing an additional 16,543 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Royal Bank Of Canada boosted their price objective on shares of Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday. Zacks Research raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group increased their price objective on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Truist Financial lifted their target price on shares of Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Guggenheim reissued a “buy” rating and issued a $175.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $188.10.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $177.49 on Wednesday. The firm has a market capitalization of $17.85 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 0.69 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $178.75. The firm’s 50-day moving average is $157.87 and its two-hundred day moving average is $142.16.

Insider Activity at Neurocrine Biosciences

In other news, Director Richard F. Pops sold 15,000 shares of Neurocrine Biosciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. The trade was a 30.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of Neurocrine Biosciences stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total transaction of $5,770,298.14. Following the sale, the insider directly owned 22,374 shares of the company’s stock, valued at approximately $3,495,266.28. This trade represents a 62.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 365,234 shares of company stock worth $57,031,540 over the last ninety days. 4.60% of the stock is currently owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.